Researchers find way to improve immunotherapy drugs’ impact while limiting side effects – News-Medical.net
|
Researchers find way to improve immunotherapy drugs’ impact while limiting side effects
News-Medical.net By connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab) and anti-PD-L1 (atezolizumab) to peptides that bind to tissues in and around tumors, a research team based at the University of Chicago found a way to improve the … |
|
Researchers find way to improve immunotherapy drugs’ impact while limiting side effects
News-Medical.net By connecting highly effective cancer immunotherapy drugs such as anti-CTLA4 (ipilimumab) and anti-PD-L1 (atezolizumab) to peptides that bind to tissues in and around tumors, a research team based at the University of Chicago found a way to improve the … |
Medscape |
Stem Cell Gene Therapy Replaces Boy’s Entire Epidermis – Medscape
Medscape Ex vivo gene therapy of epidermal cells from a boy with junctional epidermolysis bullosa enabled grafts to completely replace his epidermis. Regeneration of the entire human epidermis using transgenic stem …Nature.com |
ABC Online |
Gene therapy could cure Spinal Muscular Atrophy
ABC Online A criticism is often levelled at pharmaceutical companies that they don’t seek to cure diseases – they only seek to find a long-term drug treatment which allows you to live with the disease. In the last week, two breakthroughs for treatment of Spinal … |
News-Medical.net |
New gene therapy trial for X-linked myotubular myopathy offers hope to children
News-Medical.net Ann & Robert H. Lurie Children’s Hospital of Chicago is one of the few centers participating in ASPIRO, an international Phase 1/2 clinical trial of a gene therapy product called AT132 for X-linked myotubular myopathy – a rare disease characterized by … |
Madison.com |
This Gene Therapy Can Restore Vision, but Will It Break the Bank?
Motley Fool Luxturna is a gene therapy to treat patients with vision loss from biallelic RPE65 mutation-associated retinal dystrophy. It’s administered by subretinal injection, and in trials, it’s been shown to restore vision in more than 90% of patients for up to … Spark gene therapy for blindness could come at steep costBioPharma Dive |